Please login to the form below

Not currently logged in
Email:
Password:

pancreatic adenocarcinoma.

This page shows the latest pancreatic adenocarcinoma. news and features for those working in and with pharma, biotech and healthcare.

EU green light for Novartis' skin cancer therapy

EU green light for Novartis' skin cancer therapy

Other studies of the drug are ongoing in prostate cancer, pancreatic adenocarcinoma, ovarian cancer, non-small cell lung cancer and triple-negative breast cancer, as well as haematological malignancies such as

Latest news

  • BMS and Celgene to research cancer immunotherapy combo BMS and Celgene to research cancer immunotherapy combo

    Positive study results would also benefit Celgene, which currently markets Abraxane as a treatment for pancreatic cancer and metastatic breast cancer. ... pancreatic adenocarcinoma will be treated with Abraxane, gemcitabine and Opdivo.

  • BMS and Celgene to research cancer immunotherapy combo BMS and Celgene to research cancer immunotherapy combo

    Positive study results would also benefit Celgene, which currently markets Abraxane as a treatment for pancreatic cancer and metastatic breast cancer. ... pancreatic adenocarcinoma will be treated with Abraxane, gemcitabine and Opdivo.

  • Merck KGaA starts third phase III trial for cancer hope TH-302 Merck KGaA starts third phase III trial for cancer hope TH-302

    Merck KGaA has started a phase III trial of its novel cancer candidate TH-302 in patients with locally advanced or metastatic pancreatic adenocarcinoma. ... The new phase III trial -called MAESTRO - aims to enrol 600 patients and will compare TH-302 plus

  • Amgen-Takeda's ganitumab fails in pancreatic cancer study

    Amgen-Takeda's ganitumab fails in pancreatic cancer study. Interim analysis shows no improvement in overall survival. ... The phase III trial - codenamed GAMMA - was looking at the effects on survival of adding ganitumab to gemcitabine in the first-line

  • RNA interference rebirth RNA interference rebirth

    pancreatic adenocarcinoma. I. ALN-VSP. Alnylam. VEGF/KSP. liver cancers. I. ALN-TTR. Alnylam.

More from news
Approximately 1 fully matching, plus 5 partially matching documents found.

Latest from PMHub

  • Enablers of drug innovation could lie in the numbers

    Take the pancreatic adenocarcinoma scenario for example, if the drug developers had targeted their research in Europe instead of the USA, one could have found a much more favourable research environment. ... 7) EpiomicTM Patient Segmentation Database,

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Havas Life Medicom

We’re a specialist-led, unified communications agency delivering connected healthcare communications, informed through fresh insights, smart thinking and inspired ideas. Our...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics